FDA Guidelines on Tobacco Product Analysis and Testing Methods Validation

Jan.07
FDA Guidelines on Tobacco Product Analysis and Testing Methods Validation
FDA releases finalized guidelines on tobacco product analysis testing methods, providing manufacturers with support for regulatory submissions.

On January 6, the U.S. Food and Drug Administration (FDA) released the final version of the "Validation and Confirmation of Tobacco Product Analysis Methods" guidance, providing information and recommendations for tobacco manufacturers to support their submissions.


This guide provides detailed instructions for manufacturers on how to submit verified and validated data on analysis procedures and testing methods to the FDA for use in submissions including premarket tobacco product applications, substantial equivalence reports, and modified risk tobacco product applications.


Before being able to legally sell new tobacco products or modified risk tobacco products in the United States, companies must first submit an application to the FDA and receive approval. These applications typically require data and information to support the analytical methods used for testing tobacco products, and this guideline provides manufacturers and laboratories with scientifically sound information organization and presentation methods.


The principles described in this guide can also be applied to the writing of reports on harmful and potentially harmful constituents data required by tobacco product manufacturers and importers.


The draft version of this guide was released in 2021, allowing the public to provide feedback on the content. After considering this feedback, the FDA made adjustments to the final version of the guide, including updating the definition of "tobacco products" to include non-tobacco nicotine, adjusting the content to reflect the final PMTA and SE regulations, and updating and adding definitions for multiple terms. The final version of the guide also includes updated examples of alternative validation methods.


These suggestions are not legally binding and do not create legal obligations. In addition, the FDA acknowledges that there may be alternative validation procedures, such as statistical testing, that differ from the recommendations in this guide.


For applicants looking to introduce new tobacco products into the market, the FDA promises to continue providing information and resource support, including this recently released guide. The FDA has already issued regulations such as the PMTA final rule and regularly posts additional resources on its website and social media, such as application tips and webinars.


Compliance experts and consultants have provided the following analysis of the guidelines.


The U.S. FDA has issued this guide to provide tobacco manufacturers with guidance on conducting scientific validation and confirmation of analytical testing methods when submitting PMTA (premarket tobacco product application), SE (substantial equivalence application), and MRTPA (modified risk tobacco product application). This guide focuses on analytical testing of tobacco product ingredients, components, and additives, as well as issues related to chemical stability testing of finished tobacco products. It can also be used to guide testing and analysis of harmful and potentially harmful constituents (HPHC) in finished tobacco products, as well as other smoke or aerosol emissions. The guide aims to assist tobacco product manufacturers and analytical laboratories in collecting and presenting scientifically valid data and information to support analytical methods for submission to regulatory authorities for finished tobacco products. The recommendations in this guide will help the FDA better understand and evaluate the reliability of the data provided in regulatory submissions.


Click to read the final version of the guidelines for the validation and confirmation of analytical methods for tobacco products.


Readers are welcome to leave comments and get in touch with 2Firsts. Please contact: info@2firsts.com, or connect with 2Firsts CEO Alan Zhao on LinkedIn.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

UK Peer Seeks to Weaken “Generational Smoking Ban” – Report Reveals Discussions with BAT Executive Relative
UK Peer Seeks to Weaken “Generational Smoking Ban” – Report Reveals Discussions with BAT Executive Relative
Lord Strathcarron, a member of the UK House of Lords, has admitted to discussing the government’s Tobacco and Vapes Bill with a relative who holds a senior role at British American Tobacco (BAT). He is advocating amendments to scrap the bill’s core “generational smoking ban” provision, raising questions of potential conflict of interest.
Oct.27
2Firsts Feature | The “Pink Tax” in Vaping: How Women-Centric Design and Pricing Are Recasting the Competitive Landscape
2Firsts Feature | The “Pink Tax” in Vaping: How Women-Centric Design and Pricing Are Recasting the Competitive Landscape
Overseas e-cig brands are embracing “for her” designs, turning devices into fashion accessories. 2Firsts notes a new “pink tax” emerging through design and pricing, reflecting shifting gender and branding strategies.
Oct.20
Exclusive Interview | What’s Changing in Cigars? A Data Firm’s Perspective on the Industry’s Turning Point
Exclusive Interview | What’s Changing in Cigars? A Data Firm’s Perspective on the Industry’s Turning Point
As regulations tighten, consumer habits evolve, and new nicotine products reshape the market, the cigar industry is undergoing a quiet but profound transformation. In this exclusive interview, 2Firsts speaks with Cigar Sense — a data-driven sensory analysis firm — to explore what’s really changing in cigars, and what it means for manufacturers, retailers, and smokers around the world.
Nov.10
Feature | Vape Politics in Russia: Local Governments Push Forward Despite Legislative Deadlock
Feature | Vape Politics in Russia: Local Governments Push Forward Despite Legislative Deadlock
As Russia’s federal vape policy stalls, regional governors are racing to implement local bans—now with the backing of President Vladimir Putin. The divide between swift local action and delayed national legislation is fueling debate over health, regulation, and the country’s broader approach to nicotine control.
Oct.28
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
The U.S. Food and Drug Administration (FDA) has added Cytisinicline, a plant-based therapy developed by Achieve Life Sciences for nicotine vaping addiction, to its new National Priority Voucher (CNPV) program. The initiative shortens drug review timelines from 10–12 months to just 1–2 months, expediting approval for treatments that address major public health needs.
Oct.20 by 2FIRSTS.ai
BAT Japan to raise prices of glo heated-tobacco sticks by about 4%–5%
BAT Japan to raise prices of glo heated-tobacco sticks by about 4%–5%
BAT Japan said it will raise retail prices by ¥20 (about $0.13) per pack for 16 glo heated-tobacco stick brands—11 Lucky Strike and five Kent—effective January 1, 2026. The company will also lift prices for 12 VELO nicotine pouch brands by ¥20–¥40 per pack from December 1, 2025.
Oct.21 by 2FIRSTS.ai